Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Biomater Adv ; 158: 213775, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38252986

ABSTRACT

The current paradigm of medicine is mostly designed to block or prevent pathological events. Once the disease-led tissue damage occurs, the limited endogenous regeneration may lead to depletion or loss of function for cells in the tissues. Cell therapy is rapidly evolving and influencing the field of medicine, where in some instances attempts to address cell loss in the body. Due to their biological function, engineerability, and their responsiveness to stimuli, cells are ideal candidates for therapeutic applications in many cases. Such promise is yet to be fully obtained as delivery of cells that functionally integrate with the desired tissues upon transplantation is still a topic of scientific research and development. Main known impediments for cell therapy include mechanical insults, cell viability, host's immune response, and lack of required nutrients for the transplanted cells. These challenges could be divided into three different steps: 1) Prior to, 2) during the and 3) after the transplantation procedure. In this review, we attempt to briefly summarize published approaches employing biomaterials to mitigate the above technical challenges. Biomaterials are offering an engineerable platform that could be tuned for different classes of cell transplantation to potentially enhance and lengthen the pharmacodynamics of cell therapies.


Subject(s)
Biocompatible Materials , Regenerative Medicine , Biocompatible Materials/therapeutic use , Biocompatible Materials/pharmacology , Regenerative Medicine/methods , Tissue Engineering/methods , Cell- and Tissue-Based Therapy , Cell Transplantation
2.
Sensors (Basel) ; 22(10)2022 May 20.
Article in English | MEDLINE | ID: mdl-35632286

ABSTRACT

The rapid increase in illicit drug use and its adverse health effects and socio-economic consequences have reached alarming proportions in recent years. Surface-enhanced Raman scattering (SERS) has emerged as a highly sensitive analytical tool for the detection of low dosages of drugs in liquid and solid samples. In the present article, we review the state-of-the-art use of SERS for chemical analysis of illicit drugs in aqueous and complex biological samples, including saliva, urine, and blood. We also include a review of the types of SERS substrates used for this purpose, pointing out recent advancements in substrate fabrication towards quantitative and qualitative detection of illicit drugs. Finally, we conclude by providing our perspective on the field of SERS-based drug detection, including presently faced challenges. Overall, our review provides evidence of the strong potential of SERS to establish itself as both a laboratory and in situ analytical method for fast and sensitive drug detection and identification.


Subject(s)
Body Fluids , Illicit Drugs , Saliva , Spectrum Analysis, Raman/methods , Substance Abuse Detection
3.
Anal Bioanal Chem ; 413(5): 1441-1452, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33388843

ABSTRACT

A cost-effective, point of care (POC) device based on highly oriented CNT arrays was developed as an electrochemical assay for real-time and sensitive detection of glucose in complex samples. A low-cost, microcontroller-based potentiostat consisting of Arduino Due and LMP9100-EVM was developed to perform electrochemical measurements such as cyclic voltammetry (CV) and amperometry. A syringe pump based on open-source electronics was designed to direct the flow through a microfluidic chip. Vertically aligned carbon nanotube (VACNT) sensor arrays, in combination with the miniature potentiostat and the syringe pumps, were utilized as a POC device for the rapid and accurate detection of glucose. The structure and morphology of samples were characterized by field emission scanning electron microscopy (FESEM) and attenuated total reflectance Fourier transform infrared spectrometry (ATR-FTIR). CV as well as electrochemical impedance spectroscopy (EIS) was performed to investigate the electrochemical behavior of the electrode with respect to different diffusion regimes. The mediator-less biosensor had a limit of detection of 23 µM and sensitivity of 1462 µA mM-1 cm-2 and 1050 µA mM-1 cm-2 at the linear range of 1.2-7.8 mM and 7.8-11.2 mM, respectively. The presence of other biological compounds such as uric acid (UA) and ascorbic acid (AA) did not interfere with the detection of glucose. Finally, the designed POC device was successfully applied for the determination of glucose in human blood plasma samples.


Subject(s)
Biosensing Techniques/instrumentation , Blood Glucose/analysis , Microfluidic Analytical Techniques/instrumentation , Electrochemical Techniques/instrumentation , Electrodes , Equipment Design , Humans , Limit of Detection , Nanotubes, Carbon/chemistry , Point-of-Care Systems , Reproducibility of Results
4.
Talanta ; 222: 121518, 2021 Jan 15.
Article in English | MEDLINE | ID: mdl-33167228

ABSTRACT

A miniaturized system of anion exchange solid phase extraction (SPE) based on a screen-printed electrode was developed as a point of care (POC) device for extraction and quantitative determination of anionic analytes. Nylon 6/polyaniline nanofibers were fabricated by electrospinning and in-situ oxidative polymerization techniques coated on a screen-printed working electrode and characterized by Fourier-transform infrared spectroscopy (FTIR) and scanning electron microscopy (SEM) methods. The effects of essential parameters such as desorption conditions, pH of the sample solution, adsorption voltage, adsorption time, and salt concentration on the performance of the method were investigated. To evaluate the performance of the system, angiotensin ΙΙ receptor antagonists, including valsartan, losartan, and irbesartan, were selected as model compounds and analyzed by HPLC/UV after extraction. The limits of detection and quantification were ranging between 0.4 and 0.9 µg L-1 and 1.3-3.0 µg L-1, respectively. The linear dynamic range for Losartan, Irbesartan, and Valsartan was 2-400, 4-1000, and 2-400 µg L-1, respectively, with R2 > 0.991. Finally, the method was applied for the determination of ARA-IIs in human blood plasma samples, and relative recoveries in the range of 89.0-107.8% with relative standard deviation (RSDs (≤8.9% were obtained.


Subject(s)
Angiotensin Receptor Antagonists , Point-of-Care Systems , Adsorption , Anions , Chromatography, High Pressure Liquid , Humans , Solid Phase Extraction
SELECTION OF CITATIONS
SEARCH DETAIL
...